Skip to main navigation Skip to search Skip to main content

An Expert Consensus-Based Review of Considerations for Developing a Quality Management System Framework for Studies Utilising Secondary Data for Real-World Evidence Generation

  • Deborah Layton*
  • , Antonella Porta
  • , Dony Patel
  • , Darmendra Ramcharran
  • , Yola Moride
  • , Andrea Splendiani
  • , Tzuyung Douglas Kou
  • , Efe Eworuke
  • , Judit Riera-Arnau
  • , Smitha Sreedharan
  • , Susan A Oliveria
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

High-quality pharmacoepidemiological research is essential for credible real-world evidence (RWE). This expert consensus-based review explores how pharmaceutical Quality Management Systems (QMS) developed for studies using primary data collection (e.g., clinical trials, registries) can be adapted to support studies utilising secondary data to generate RWE, in line with regulatory expectations. The aim was to identify fit-for-purpose considerations for proportional oversight, data integrity, and regulatory-grade evidence generation. An international working group (WG) comprising RWE experts from industry, academia, and independent consultancy (including QMS specialist) assessed which elements of QMS frameworks developed for primary data collection are applicable to RWE studies utilising secondary data sources and those elements where adaptation would be required. Using the Nominal Group Technique, the WG identified and prioritised relevant quality systems and adaptation needs. In parallel, a targeted literature review of guidance and reports from International Coalition of Medicines Regulatory Authorities (ICMRA) member sites (focusing on the EU, USA and UK) assessed guidance against prioritized quality systems. Of 21 quality systems identified, 12 were considered most relevant to RWE studies utilising secondary data, with ten requiring contextual adaptations. The literature review identified 26 publications referencing one or more of these systems; quality manuals (69.2% (n = 18)) and quality control (34.6% (n = 9)) were most frequently addressed, whilst other systems were inconsistently covered; vendor management was not explicitly addressed. Overall, this review highlights the need for fit-for-purpose adaptation of existing QMS frameworks to support regulatory-relevant, scientifically robust RWE generated from secondary use of existing data sources.

Original languageEnglish
Pages (from-to)249-263
JournalPharmaceutical medicine
Volume40
Early online date6 Jun 2026
DOIs
Publication statusPublished - Jul 2026

Fingerprint

Dive into the research topics of 'An Expert Consensus-Based Review of Considerations for Developing a Quality Management System Framework for Studies Utilising Secondary Data for Real-World Evidence Generation'. Together they form a unique fingerprint.

Cite this